ALT
Altimmune, Inc.
A clinical-stage biopharmaceutical company developing pemvidutide, a balanced GLP-1 and glucagon dual receptor agonist in late-stage trials for fatty-liver disease (MASH), alcohol use disorder, and alcohol-associated liver disease. It began in 1997 as vaccine maker Vaxin Inc. before renaming to Altimmune in 2015, and its early work included NasoVAX, a needle-free intranasal flu vaccine.
CUSIP: 02155H200HealthcareUS1 holder
Total Value
$20.37M
Total Shares
6.70M
Net Share Change
+6.70M
Activity
1 buying
Investor
Value
Shares
Weight
Change
